Insulin Delivery Systems

Target Audience
Pharmacists, nurses, and dietitians who are involved with patient education and counseling.

Goal
To understand the choices available to administer insulin.

Objectives
After completing this activity, the participant should be able to do the following:

Review key findings of the Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS).
State three current options for insulin delivery.
Compare traditional vial and syringe insulin administration to other insulin delivery systems.
Identify two insulin delivery systems in research and development.

Pharmacists

The American Association of Diabetes Educators and Novo Nordisk Pharmaceuticals, Inc. are accredited by the American Council on Pharmaceutical Education (ACPE) as providers of continuing pharmaceutical education. This program provides for 1.0 contact hours (0.1 CEUs) of continuing education credit. ACPE Universal Program Number 069-360-01-696-H04

Nurses

Registered Nurses: This program for 1.2 contact hours has been approved by the American Association of Diabetes Educators which is accredited as an approver of continuing education in nursing by the American Nurses Credentialing Center's Commission of Accreditation. Approval of this continuing education activity does not imply endorsement by AADE. Approval number 0102-05

Dietitians

American Association of Diabetes Educators (AM001) is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR) from June 1, 2003 to May 31, 2006. Registered dietitians (RD) and dietetic technicians, registered (DTR) will receive 1.0 Continuing Professional Education Unit (CPEU) for completion of this program. Continuing Professional Education Provider Accreditation does not constitute endorsement by CDR of a provider, program, or materials.

Initial Release Date: September 28, 2001
Planned Expiration Date: September 28, 2003

To receive a statement of credit, you must:

Successfully complete the post-test (70% or better).
Complete the program evaluation.

Your statement of credit will be issued immediately upon successful completion of the test and submission of the evaluation form. The statement of credit specific to your discipline will appear on your screen and you will be given the option to print it for your files. No additional statement of credit will be issued.

Activity Presenter

Virginia Peragallo-Dittko, RN, MA, CDE
Virginia Peragallo-Dittko is the Director for the Diabetes Education Center at Winthrop University Hospital in Mineola, NY. She is responsible for coordination of the Diabetes Education Center and for the delivery of group and individual instruction.

Virginia has been a diabetes nurse specialist in a variety of settings since 1979. In 1990 she was named Diabetes Educator of the Year by the American Association of Diabetes Educators. She has been a member of the Editorial Board of The Diabetes Educator journal since 1985 and she is the editor of the textbook, A Core Curriculum for Diabetes Education (2nd edition and Addendum). Virginia has been published in the area of diabetes education in books, lay and professional journals, has lectured extensively for lay and professional audiences, and has participated in radio and television interviews.

Fee
There is no fee to receive credits for this program.

Commercial Supporter
This program has been supported through an unrestricted educational grant from Novo Nordisk Pharmaceuticals, Inc.

Autopen is a registered trademark of Owen - Mumford Company. B-D Pen is a registered trademark of Becton Dickinson. Disetronic Pen is a registered trademark of Disetronic. Humulin & Humalog Pen Humalog, Humalog Mix 75/25 are registered trademarks of Eli Lilly. NovoPen 1.5, NovoPen 3, NovoFine 30, Innovo, NovoLog, PenFill, Lente, Ultralente, and Velosulin BR are registered trademarks of Novo Nordisk A/S. Novolin Prefilled is a trademark of Novo Nordisk A/S. Lantus is a registered trademark of Aventis.

Disclosure Declaration
It is the policy of Novo Nordisk Pharmaceuticals, Inc. and the American Association of Diabetes Educators to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with the commercial companies whose products or devices may be mentioned in the activity or with the supporter of this continuing education activity. The information is for participant information; it is not assumed that these relationships will have a negative impact on the content of the activity.

Ms. Peragallo-Dittko has disclosed that she has received an honorarium for narrating this activity.

Disclaimers

Approval of credit for this continuing education program does not imply endorsement by AADE of any product or manufacturer identified.
Any medications or treatment methods suggested in this CE activity should not be used by the practitioner without evaluation of their patient's condition(s) and possible contraindication(s) or danger(s) of use of any specific medication.
This activity may include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA).
Novo Nordisk Pharmaceuticals, Inc., the American Association of Diabetes Educators, and the activity's faculty do not endorse the use of any product in a manner that is not approved by the FDA.

The author, sponsor, and publisher of this continuing education program have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education program. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.

NOTE: All confidential data collected during the registration process is encrypted
for secure transmission over the internet.
Click here to read the CECity Privacy Statement

Pharmacists Click Here to Continue

Nurses Click Here to Continue

Dietitians Click Here to Continue

The Slides and Audio portion of this activity requires the FREE Real Player.

Click here to download the
FREE Basic Real Player